Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a company dedicated to developing innovative, non-invasive diagnostic testing solutions that aim to improve quality of life. They leverage advanced technology to create portable, accurate, and accessible testing systems for various health conditions, including diabetes and drug abuse detection. Their mission is to redefine testing approaches and deliver transformative health solutions globally.
Industries
Nr. of Employees
medium (51-250)
Intelligent Bio Solutions
135 W 41st St Floor 5, New York, NY 10036, United States
Products
Portable fingerprint-sweat drug screening system
A point-of-care system consisting of a portable reader and single-use tamper-evident cartridges that collects multiple fingertip sweat samples in under a minute and provides multi-drug screening results on-screen in approximately ten minutes.
Saliva glucose biosensor (printable OTFT strip)
A non-invasive, point-of-care saliva glucose biosensor using an organic thin-film transistor with an enzymatic recognition element to produce real-time glucose measurements intended as an alternative to finger‑prick blood glucose testing.
SARS-CoV-2 antibody biosensor (electrochemical/transistor integration)
Rapid point-of-care antibody assay under development that integrates electrochemical affinity-based sensing chemistries with a transistor-based readout to detect SARS-CoV-2 antibodies from plasma or saliva with short time-to-result.
Portable fingerprint-sweat drug screening system
A point-of-care system consisting of a portable reader and single-use tamper-evident cartridges that collects multiple fingertip sweat samples in under a minute and provides multi-drug screening results on-screen in approximately ten minutes.
Saliva glucose biosensor (printable OTFT strip)
A non-invasive, point-of-care saliva glucose biosensor using an organic thin-film transistor with an enzymatic recognition element to produce real-time glucose measurements intended as an alternative to finger‑prick blood glucose testing.
SARS-CoV-2 antibody biosensor (electrochemical/transistor integration)
Rapid point-of-care antibody assay under development that integrates electrochemical affinity-based sensing chemistries with a transistor-based readout to detect SARS-CoV-2 antibodies from plasma or saliva with short time-to-result.
Services
Laboratory-based confirmatory testing service for positive rapid drug screens.
Regional sales team, distribution hub and office facility to scale distribution, customer service and operations for portable drug screening systems across the Asia-Pacific region.
On-site and remote product demonstrations and deployment support for portable sweat-based drug screening systems.
Laboratory-based confirmatory testing service for positive rapid drug screens.
Regional sales team, distribution hub and office facility to scale distribution, customer service and operations for portable drug screening systems across the Asia-Pacific region.
On-site and remote product demonstrations and deployment support for portable sweat-based drug screening systems.
Expertise Areas
- Non-invasive point-of-care diagnostics
- Workplace drug screening and rapid toxicology screening
- Printable organic electronic biosensor development
- Clinical study design and validation for diagnostic devices
Key Technologies
- Organic thin-film transistor (OTFT) biosensors
- Fingerprint-sweat biomarker analysis
- Roll-to-roll printable organic electronics
- Affinity-based electrochemical sensing
News & Updates
An article discussing the importance and methods of workplace drug testing, highlighting the use of fingerprint drug testing systems.
INBS to participate with U.S. distribution partner SMARTOX at RISE25, a leading U.S. conference on addiction, mental health, and justice innovation.
GBS Inc. has acquired Intelligent Fingerprinting Limited, expanding its portfolio of rapid, non-invasive diagnostic testing technologies, including fingerprint sweat-based drug screening systems.
A collaboration to validate and de-risk a COVID-19 diagnostic integrating Wyss Institute’s eRapid technology with GBS’s biosensor platform.
GBS received a significant grant to establish a high-tech medical device manufacturing facility in Australia for biosensor production.
Completion of a clinical study evaluating glucose levels in oral fluids and blood, supporting the development of non-invasive glucose monitoring.
An article discussing the importance and methods of workplace drug testing, highlighting the use of fingerprint drug testing systems.
INBS to participate with U.S. distribution partner SMARTOX at RISE25, a leading U.S. conference on addiction, mental health, and justice innovation.
GBS Inc. has acquired Intelligent Fingerprinting Limited, expanding its portfolio of rapid, non-invasive diagnostic testing technologies, including fingerprint sweat-based drug screening systems.
A collaboration to validate and de-risk a COVID-19 diagnostic integrating Wyss Institute’s eRapid technology with GBS’s biosensor platform.
GBS received a significant grant to establish a high-tech medical device manufacturing facility in Australia for biosensor production.
Completion of a clinical study evaluating glucose levels in oral fluids and blood, supporting the development of non-invasive glucose monitoring.